Author + information
- S. Okar,
- O. Kaypakli,
- D.Y. Sahin and
- M. Koc
We aimed to investigate the relationship between the recurrence of AF and fibrosis marker sST2 in patients with nonvalvular PAF.
We prospectively included 100 consecutive patients with PAF diagnosis and scheduled for cryoballoon catheter ablation for atrial fibrillation (47 male, 53 female; mean age 55,1±10,8 years). sST2 plasma levels were determined using the ASPECT-PLUS assay on ASPECT Reader device (Critical Diagnostics, San Diego, CA, USA). The measurement range of these measurements was 12.5-250 ng / mL. Patients had regular follow-up visits with 12-lead ECG, medical history and clinical evaluation. 24 h Holter ECG monitoring had been recorded 12 months after ablation.
AF recurrence was detected in 22 patients after 1 year. Patients were divided into two groups according to the AF recurrence. All parameters were compared between the two groups. Age, smoking history, DM, HT frequency, ACEI-ARB use, CHA2DS2VASc and HASBLEED score, serum sST2 level, LA end-diastolic diameter, LA volume and LA volume index were related to AF recurrence. In binary logistic regression analysis, sST2 was found to be only independent parameter for predicting AF recurrence (OR=1.085) (p=0.001). The cut-off value of sST2 obtained by ROC curve analysis was 30,6 ng/mL for prediction of AF recurrence (sensitivity: 77.3%, specificity: 79.5%). The area under the curve (AUC) was 0.831 (p<0.001).
Soluble ST2, which is associated with atrial fibrosis, can be thought to be a useful marker for detection of patients with high-grade fibrosis who will get less benefit from cryoablation.